

Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Generic Name:	bevacizumab
Brand Name:	Avastin
Strength:	100mg/4mL vial and 400mg/16mL vial IV solution
Manufacturer:	Hoffmann-La Roche Ltd.
Indication:	In combination with paclitaxel for the treatment of metastatic breast cancer (New indication)
Rapid Review:	Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	02/03/2009	03/04/2009	EO decision rendered	Funding not available through Cancer Care Ontario's New Drug Funding Program
Reconsideration (Resubmission #1)	21/12/2009	19/02/2010	EO decision rendered	Funding not available through Cancer Care Ontario's New Drug Funding Program

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:

- Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Decision:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Updated: July 5, 2011